Kentucky Childrens Hospital Neonatal Intensive Care Unit
Lexington, Kentucky, 40506, United States
NCT Number: NCT02221219
Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) are brain lesions that commonly occur in preterm infants and are well-recognized major contributors to long-term brain injury and related disabilities later in life. Despite its prevalence, long term consequences, and enormous medical and social costs, mechanisms of IVH and optimal strategies to prevent or treat its occurrence are poorly defined, especially for extremely premature infants. Only one medical therapy, prophylactic indomethacin during the first 3 days of life, has been shown to prevent or decrease the severity of IVH in preterm infants, but its use is limited by toxic side effects and debatable effects on long-term outcomes. Several small studies and case reports suggest that delayed umbilical cord-clamping (DCC) may also decrease the incidence of IVH in premature infants, but thus far these trials have indomethacin treatment mixed within their cord clamping protocols. The investigators are conducting a randomized, blinded investigation of 4 treatment groups: 1) Control (no intervention); 2) DCC alone; 3) Prophylactic indomethacin alone; 4) Combination of DCC/indomethacin, with respect to survival, IVH or PVL incidence and severity, neurodevelopmental outcomes, and relevant mechanistic effects. With the steady rise in extreme prematurity births and clear links of IVH to long-term disabilities there is a need to improve care for these patients. This multi- disciplinary project addresses an important medical problem for an understudied patient population, where the current practice has clear limitations.
Looking for future studies?
Notify Me24 week–30 week
All sexes
Interventional
Phase 1 / Phase 2
Lexington, Kentucky, 40506, United States
The investigators will compare efficacy and safety of prophylactic indomethacin, DCC, and their combination, in affecting the incidence and severity of IVH/PVL in infants <30wks gestational age (primary outcome measure of 'fraction of survivors with no severe IVH or PVL' among the 4 groups), and longer term neurocognitive function. Other secondary endpoints and investigations include mechanistic effects of prophylactic indomethacin, DCC, and their combination (blood volume/circulatory status, inflammatory stress, progenitor cells) as well as defining relationships between clinical outcomes and mechanistic measurements among treatment groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Other names: indocin
provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
no delay in umbilical cord clamp; <10sec (recorded in delivery note)
Time frame: within first 60 days of life
determined by head ultrasound in Neonatal Intensive Care Unit (NICU) and single head MRI at 38weeks corrected gestational age
Time frame: first 60 days of life
measures of serum creatinine and urine output during Neonatal Intensive Care Unit (NICU) stay. General measures of renal injury (which is a common risk of indomethacin treatment in this patient population).
Time frame: first 60 days of life
hematocrit, ferritin, hemoglobin at various times during NICU stay
Time frame: first 60 days of life
measurement of inflammatory biomarkers (CRP, Interleukin-6, soluble ICAM) at various times during NICU stay
Time frame: first 60 days of life
measures of several progenitor cell subtypes in blood during the NICU stay
Time frame: up to 24 months of corrected gestational age
standardized neurocognitive assessments done at NICU graduate clinic.
Hong Huang
Other
Indomethacin and Delayed Umbilical Cord Clamp for Preterm Infant IVH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02814383
Brain Diseases, Brain Injuries
Houston, Texas, United States
View Trial DetailsNCT02784821
Bacteremia, Bacterial Infections
Gainesville, Florida, United States
View Trial DetailsNCT04535375
Brain Diseases, Cardiovascular Diseases
Brussels, Brussels Capital, Belgium
View Trial DetailsNCT04077333
Brain Diseases, Bronchopulmonary Dysplasia
Beijing, China
View Trial Details